183 related articles for article (PubMed ID: 24324968)
1. Novel natural structure corrector of ApoE4 for checking Alzheimer's disease: benefits from high throughput screening and molecular dynamics simulations.
Goyal M; Grover S; Dhanjal JK; Goyal S; Tyagi C; Chacko S; Grover A
Biomed Res Int; 2013; 2013():620793. PubMed ID: 24324968
[TBL] [Abstract][Full Text] [Related]
2. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons.
Chen HK; Liu Z; Meyer-Franke A; Brodbeck J; Miranda RD; McGuire JG; Pleiss MA; Ji ZS; Balestra ME; Walker DW; Xu Q; Jeong DE; Budamagunta MS; Voss JC; Freedman SB; Weisgraber KH; Huang Y; Mahley RW
J Biol Chem; 2012 Feb; 287(8):5253-66. PubMed ID: 22158868
[TBL] [Abstract][Full Text] [Related]
3. Lipidated apolipoprotein E4 structure and its receptor binding mechanism determined by a combined cross-linking coupled to mass spectrometry and molecular dynamics approach.
Henry N; Krammer EM; Stengel F; Adams Q; Van Liefferinge F; Hubin E; Chaves R; Efremov R; Aebersold R; Vandenbussche G; Prévost M; Raussens V; Deroo S
PLoS Comput Biol; 2018 Jun; 14(6):e1006165. PubMed ID: 29933361
[TBL] [Abstract][Full Text] [Related]
4. Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer.
Petros AM; Korepanova A; Jakob CG; Qiu W; Panchal SC; Wang J; Dietrich JD; Brewer JT; Pohlki F; Kling A; Wilcox K; Lakics V; Bahnassawy L; Reinhardt P; Partha SK; Bodelle PM; Lake M; Charych EI; Stoll VS; Sun C; Mohler EG
J Med Chem; 2019 Apr; 62(8):4120-4130. PubMed ID: 30933499
[TBL] [Abstract][Full Text] [Related]
5. Concerning the structure of apoE.
Frieden C; Garai K
Protein Sci; 2013 Dec; 22(12):1820-5. PubMed ID: 24115173
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanisms of the R61T Mutation in Apolipoprotein E4: A Dynamic Rescue.
Williams B; Convertino M; Das J; Dokholyan NV
Biophys J; 2017 Nov; 113(10):2192-2198. PubMed ID: 28916386
[TBL] [Abstract][Full Text] [Related]
7. Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction.
Adeosun SO; Hou X; Zheng B; Stockmeier C; Ou X; Paul I; Mosley T; Weisgraber K; Wang JM
J Biol Chem; 2014 Jan; 289(5):2946-59. PubMed ID: 24324264
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease.
Chen HK; Ji ZS; Dodson SE; Miranda RD; Rosenblum CI; Reynolds IJ; Freedman SB; Weisgraber KH; Huang Y; Mahley RW
J Biol Chem; 2011 Feb; 286(7):5215-21. PubMed ID: 21118811
[TBL] [Abstract][Full Text] [Related]
9. Proposal of novel ApoE4 inhibitors from the natural spice Cinnamon for the treatment of Alzheimer's disease: Ab initio molecular simulations.
Shaji D; Das A; Suzuki R; Nagura Y; Sabishiro H; Kurita N
Biophys Chem; 2023 May; 296():106990. PubMed ID: 36898350
[TBL] [Abstract][Full Text] [Related]
10. The Molecular Basis for Apolipoprotein E4 as the Major Risk Factor for Late-Onset Alzheimer's Disease.
Raulin AC; Kraft L; Al-Hilaly YK; Xue WF; McGeehan JE; Atack JR; Serpell L
J Mol Biol; 2019 May; 431(12):2248-2265. PubMed ID: 31051176
[TBL] [Abstract][Full Text] [Related]
11. In Silico Analysis of the Antagonist Effect of Enoxaparin on the ApoE4-Amyloid-Beta (A
Aguilar-Pineda JA; Paco-Coralla SG; Febres-Molina C; Gamero-Begazo PL; Shrivastava P; Vera-López KJ; Davila-Del-Carpio G; López-C P; Gómez B; Lino Cardenas CL
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454088
[TBL] [Abstract][Full Text] [Related]
12. In Silico Design of Natural Inhibitors of ApoE4 from the Plant
Shaji D; Nagura Y; Sabishiro H; Suzuki R; Kurita N
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138525
[TBL] [Abstract][Full Text] [Related]
13. Computational design of apolipoprotein E4 inhibitors for Alzheimer's disease therapy from traditional Chinese medicine.
Huang HJ; Chen HY; Lee CC; Chen CY
Biomed Res Int; 2014; 2014():452625. PubMed ID: 24967370
[TBL] [Abstract][Full Text] [Related]
14. In silico analysis of the apolipoprotein E and the amyloid beta peptide interaction: misfolding induced by frustration of the salt bridge network.
Luo J; Maréchal JD; Wärmländer S; Gräslund A; Perálvarez-Marín A
PLoS Comput Biol; 2010 Feb; 6(2):e1000663. PubMed ID: 20140182
[TBL] [Abstract][Full Text] [Related]
15. Atomistic Insights into Structural Differences between E3 and E4 Isoforms of Apolipoprotein E.
Ray A; Ahalawat N; Mondal J
Biophys J; 2017 Dec; 113(12):2682-2694. PubMed ID: 29262361
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology.
Mahley RW; Huang Y
Acta Neurol Scand Suppl; 2006; 185():8-14. PubMed ID: 16866905
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
18. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease.
Cerf E; Gustot A; Goormaghtigh E; Ruysschaert JM; Raussens V
FASEB J; 2011 May; 25(5):1585-95. PubMed ID: 21266538
[TBL] [Abstract][Full Text] [Related]
19. ApoE4-specific Misfolded Intermediate Identified by Molecular Dynamics Simulations.
Williams B; Convertino M; Das J; Dokholyan NV
PLoS Comput Biol; 2015 Oct; 11(10):e1004359. PubMed ID: 26506597
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease: unraveling APOE4 binding to amyloid-beta peptide and lipids with molecular dynamics and quantum mechanics.
Gillet JN
J Biomol Struct Dyn; 2021 Sep; 39(14):5026-5032. PubMed ID: 32580638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
